<DOC>
	<DOCNO>NCT02959138</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics ( PK ) GS-9876 participant impair renal function relative match healthy control . Participants study enrol use adaptive design include 3 enrolled cohort . Based safety and/or PK data Cohort 1 , participant enrol adaptive Cohorts 2 and/or 3 .</brief_summary>
	<brief_title>Pharmacokinetics GS-9876 Adults With Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Key All Individuals Have ability understand sign write informed consent form ( ICF ) , must obtain prior initiation study procedure Be 18 75 year age , inclusive screening Have calculate body mass index ( BMI ) ≥ 18 kg/m^2 ≤ 36 kg/m^2 screen Females childbearing potential must negative pregnancy test screen clinic admission ( Day 1 ) . Individuals donate blood within 56 day study entry plasma within 7 day study entry must refrain blood donation clinic admission , throughout study period , continue least 30 day follow last dose study drug . Have either normal 12lead ECG one abnormality consider clinically insignificant investigator consultation sponsor Must , opinion investigator , good health base upon medical history physical examination , include vital sign For Individuals Renal Impairment Must diagnosis chronic ( &gt; 6 month ) , stable renal impairment clinically significant change renal function status within 90 day prior study drug administration ( Day 1 ) . Have creatinine clearance ( CLcr ) &lt; 90 mL/min ( use CockcroftGault method { Cockcroft et al 1976 } ) base serum creatinine actual body weight measure screening . For Healthy Matched Controlled Individuals ( Individuals Normal Renal Function ) Have creatinine clearance ( CLcr ) ≥ 90 mL/min ( use CockcroftGault method { Cockcroft et al 1976 } ) base serum creatinine actual body weight measure screen Match age ( ± 10 year ) , gender , body mass index ( ± 20 % , 18 kg/m^2 ≤ BMI ≤ 36 kg/m^2 ) . Key Exclusion Criteria Be lactate female Have receive investigational compound within 30 day prior study dose Have current alcohol substance abuse judge investigator potentially interfere individual 's compliance individual 's safety judge investigator Have positive test result human immunodeficiency virus type 1 ( HIV1 ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) , hepatitis C virus ( HCV ) antibody Have poor venous access limit phlebotomy For Individuals Renal Impairment Require anticipate require dialysis within 90 day study dose Require study receive moderate strong inhibitor inducer CYP3A within 2 week prior study drug administration . For Healthy Matched Controlled Individuals ( Individuals Normal Renal Function ) Have take prescription medication overthecounter medication , include herbal product antacid , within 28 day prior start study drug dosing , exception vitamin and/or acetaminophen and/or ibuprofen and/or hormonal contraceptive medication and/or stable hormone replacement therapy peri /postmenopausal female Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>